Literature DB >> 31642902

Cardiac perfusion, structure, and function in type 2 diabetes mellitus with and without diabetic complications.

Martin Heyn Sørensen1,2, Annemie Stege Bojer1,2, David Andrew Broadbent3,4, Sven Plein5, Per Lav Madsen6,7, Peter Gæde1,2.   

Abstract

AIMS: Coronary microvascular disease (CMD) is a known complication in type 2 diabetes mellitus (T2DM). We examined the relationship between diabetic complications, left ventricular (LV) function and structure and myocardial perfusion reserve (MPR) as indicators of CMD in patients with T2DM and control subjects. METHODS AND
RESULTS: This was a cross-sectional study of 193 patients with T2DM and 25 controls subjects. Patients were grouped as uncomplicated diabetes (n = 71) and diabetes with complications (albuminuria, retinopathy, and autonomic neuropathy). LV structure, function, adenosine stress, and rest myocardial perfusion were evaluated by cardiovascular magnetic resonance. Echocardiography was used to evaluate diastolic function. Patients with uncomplicated T2DM did not have significantly different LV mass and E/e* but decreased MPR (3.8 ± 1.0 vs. 5.1 ± 1.5, P < 0.05) compared with controls. T2DM patients with albuminuria and retinopathy had decreased MPR (albuminuria: 2.4 ± 0.9 and retinopathy 2.6 ± 0.7 vs. 3.8 ± 1.0, P < 0.05 for both) compared with uncomplicated T2DM patients, along with significantly higher LV mass (149 ± 39 and 147 ± 40 vs. 126 ± 33 g, P < 0.05) and E/e* (8.3 ± 2.8 and 8.1 ± 2.2 vs. 7.0 ± 2.5, P < 0.05). When entered in a multiple regression model, reduced MPR was associated with increasing E/e* and albuminuria and retinopathy were associated with reduced MPR.
CONCLUSIONS: Patients with uncomplicated T2DM have reduced MPR compared with control subjects, despite equivalent LV mass and E/e*. T2DM patients with albuminuria or retinopathy have reduced MPR and increased LV mass and E/e* compared with patients with uncomplicated T2DM. E/e* and MPR are significantly associated after adjustment for age, hypertension, and LV mass, suggesting a link between CMD and cardiac diastolic function. CLINICAL TRIAL REGISTRATION: https://www.clinicaltrials.org. Unique identifier: NCT02684331. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  albuminuria; cardiovascular magnetic resonance imaging; diabetes; diastolic dysfunction; myocardial perfusion reserve; retinopathy

Mesh:

Year:  2020        PMID: 31642902     DOI: 10.1093/ehjci/jez266

Source DB:  PubMed          Journal:  Eur Heart J Cardiovasc Imaging        ISSN: 2047-2404            Impact factor:   6.875


  6 in total

1.  Cardiovascular Determinants of Aerobic Exercise Capacity in Adults With Type 2 Diabetes.

Authors:  Gaurav S Gulsin; Joseph Henson; Emer M Brady; Jack A Sargeant; Emma G Wilmot; Lavanya Athithan; Zin Z Htike; Anna-Marie Marsh; John D Biglands; Peter Kellman; Kamlesh Khunti; David Webb; Melanie J Davies; Thomas Yates; Gerry P McCann
Journal:  Diabetes Care       Date:  2020-07-17       Impact factor: 19.112

Review 2.  Cardiovascular and systemic determinants of exercise capacity in people with type 2 diabetes mellitus.

Authors:  Joanna M Bilak; Gaurav S Gulsin; Gerry P McCann
Journal:  Ther Adv Endocrinol Metab       Date:  2021-01-27       Impact factor: 3.565

3.  Impact of type 2 diabetes mellitus on left ventricular diastolic function in patients with essential hypertension: evaluation by volume-time curve of cardiac magnetic resonance.

Authors:  Wei-Feng Yan; Yue Gao; Yi Zhang; Ying-Kun Guo; Jin Wang; Li Jiang; Yuan Li; Zhi-Gang Yang
Journal:  Cardiovasc Diabetol       Date:  2021-03-25       Impact factor: 9.951

4.  Multiparametric CMR imaging of myocardial structure and function changes in diabetic mini-pigs with preserved LV function: a preliminary study.

Authors:  Yukun Cao; Heshui Shi; Guozhu Shao; Yue Cui; Xiaoyu Han; Jia Liu; Yumin Li; Na Li
Journal:  BMC Cardiovasc Disord       Date:  2022-04-02       Impact factor: 2.298

5.  Fibroblast growth factor-23 is associated with imaging markers of diabetic cardiomyopathy and anti-diabetic therapeutics.

Authors:  Martin H Sørensen; Annemie S Bojer; Niklas R Jørgensen; David A Broadbent; Sven Plein; Per L Madsen; Peter Gæde
Journal:  Cardiovasc Diabetol       Date:  2020-09-30       Impact factor: 9.951

6.  Distinct non-ischemic myocardial late gadolinium enhancement lesions in patients with type 2 diabetes.

Authors:  Annemie Stege Bojer; Martin Heyn Sørensen; Niels Vejlstrup; Jens P Goetze; Peter Gæde; Per Lav Madsen
Journal:  Cardiovasc Diabetol       Date:  2020-10-22       Impact factor: 9.951

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.